Systematic Reviews
Copyright ©The Author(s) 2024.
World J Orthop. Sep 18, 2024; 15(9): 870-881
Published online Sep 18, 2024. doi: 10.5312/wjo.v15.i9.870
Table 2 Designs and conclusions of included studies
Ref.
Study design
Sample size
Age (mean)
BMI (mean)
Female
Pathology
Intervention (s)
Latest follow-up
Outcomes measured
Conclusion
Becker et al[15]Randomized prospective cohort studyACS: n = 32, 5 mg Triamcinolone: n = 27, 10 mg Triamcinolone: n = 2553.9 (range: 29-81)Not reported38.10%Lumbar radiculopathy3 weekly transforaminal injections of ACS, 5 mg triamcinolone, or 10 mg triamcinolone20 weeks post-final injectionVAS, ODIEpidural ACS injection for unilateral lumbar radiculopathy significantly improved patient pain and disability compared to baseline to an extent potentially superior to ESI. No statistically significant difference in symptom improvement was observed between 5 mg and 10 mg epidural injection of triamcinolone
Goni et al[16]Pilot studyACS: n = 20; MPS: n = 20ACS: 42.25; MPS: 46.80Not reportedACS: 40%; MPS: 45%Cervical radiculopathyA single 2-3 mL transforaminal injection of ACS or MPS6 months post-injectionVAS, NDI, NPDS, PCS, MCSPatients with cervical radiculopathy treated with epidural ACS injection experienced sustained improvement of pain, disability and quality of life. ACS produced as good or better improvement of symptoms with longer duration of relief compared to epidural methylprednisolone
HS et al[17]Prospective studyACS: n = 2037.1524.92 kg/m2Not reportedLumbar radiculopathyA single 2 mL transforaminal injection of ACS6 months post-injectionVAS, SLRT, ODI, PCS, MCSEpidural ACS injection can modify the disease course of unilateral lumbar radiculopathy by significantly improving pain, disability, and quality of life
Godek et al[19]Pilot studyACS: n = 1538.8Not reported40%Lumbar radiculopathy1-2 weekly transforaminal injections of 3-4 mL ACS6 months post-injectionVAS, ODI, SLRT, OLST, Analgesic useACS is a promising option for significantly improving pain and disability in patients with single-level lumbar radiculopathy. No radicular damage or sever adverse events were reported
Godek et al[18]Retrospective studyACS: n = 49757.1 ± 16.5 (range: 17-93)Not reported57.70%Cervical DDD (transforaminal injection): n = 89. Thoracic Spine DDD (transforaminal injection): n = 8. Lumbar Spine DDD (transforaminal injection): n = 271. Lumbar Spine DDD (interlaminar injection): n = 1. Lumbar Spine Stenosis (transforaminal injection): n = 118. Lumbar Spine Stenosis (interlaminar injection): n = 10Cervical: 4 doses of 3-4 mL transforaminal ACS injections. Thoracic: 6 doses of 3-4 mL transforaminal ACS injections. Lumbar: 4-6 doses of 4 mL ACS injected transforaminally or interlaminarly6 months post-final injectionModified McNabb scaleACS injection was well tolerated with very few and limited cases of adverse events. ACS injection produced satisfactory improvement in Modified McNabb Scale scores for patients with cervical or lumbar discopathy. Unsatisfactory results predominated in cases of lumbar spinal stenosis
Godek et al[13]Randomized control trialACS: n = 10046.29 + 13.6126.67 ± 4.4951%Lumbar Radiculopathy due to DDD (interlaminar injection): n = 50. Lumbar Radiculopathy due to DDD (transforaminal injection): n = 502 weekly interlaminar or transforaminal injections of 8 mL ACS24 weeks post-final injectionNRS, ODI, RMQ, EQ-5D-5 L mobility, EQ-5D-5 L self-care, EQ-5D-5 L usual activities, EQ-5D-5 L pain/discomfort, EQ-5D-5 L anxiety/depression, EQ-5D-5 L-based LSS, EQ-5D-5 L VAS, EQ-5D-5 L IndexEpidural and transforaminal ACS injections both significantly improve patient outcomes compared to baseline. Treatment with transforaminal ACS injection produced statistically superior improvement in EQ-5D-5 L scores compared to epidural ACS injection